Protocol Ledger

NCT06415773 · Phase III · COMPLETED

Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

Interventional Phase III clinical trial protocol NCT06415773 sponsored by Shenzhen HighTide Biopharmaceutical in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-06-04 Enrollment: 367 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06415773
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)367 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06415773
Protocol FieldVerified Registry Value
NCT IdentifierNCT06415773
Consolidated Lead SponsorShenzhen HighTide Biopharmaceutical
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment367 participants (ACTUAL)
Registered Start Date2024-06-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI